AlphaCore Capital LLC Buys 470 Shares of Stryker Corporation $SYK

AlphaCore Capital LLC boosted its stake in Stryker Corporation (NYSE:SYK) by 81.3% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,048 shares of the medical technology company’s stock after buying an additional 470 shares during the period. AlphaCore Capital LLC’s holdings in Stryker were worth $414,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of SYK. Vanguard Group Inc. increased its stake in shares of Stryker by 1.3% during the second quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock worth $13,253,831,000 after purchasing an additional 440,607 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Stryker by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after buying an additional 1,021,496 shares in the last quarter. Geode Capital Management LLC increased its position in Stryker by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock worth $2,910,445,000 after buying an additional 79,654 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Stryker by 13.1% during the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after buying an additional 261,058 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Stryker by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock valued at $776,871,000 after acquiring an additional 83,954 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SYK. Wells Fargo & Company lifted their price objective on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research note on Friday, November 14th. Evercore ISI dropped their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. BTIG Research reissued a “buy” rating and set a $410.00 price target on shares of Stryker in a research report on Friday, November 14th. Redburn Partners set a $420.00 price objective on Stryker in a report on Thursday, September 18th. Finally, Needham & Company LLC reissued a “buy” rating and set a $448.00 target price on shares of Stryker in a report on Friday, November 14th. Thirteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus target price of $434.37.

Stryker Stock Up 0.6%

Shares of NYSE:SYK opened at $370.38 on Tuesday. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The company has a market capitalization of $141.64 billion, a PE ratio of 49.06, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The company has a fifty day moving average of $369.24 and a 200-day moving average of $380.59.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the previous year, the company posted $2.87 EPS. Stryker’s quarterly revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Insider Activity at Stryker

In related news, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the sale, the chief financial officer directly owned 6,694 shares in the company, valued at $2,449,200.72. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 522,118 shares of company stock worth $185,381,932 in the last quarter. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.